Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Bankruptcies: BIND and NephroGenex Weigh Options

Executive Summary

Once-prosperous biotechs are now seeking strategic alternatives including the selling off of all of their assets now that they've failed to acquire the funds they need to move forward.

You may also be interested in...



In A BIND And Short On Cash

NephroGenex soars on cardiac safety data

US firm NephroGenex, which conducted its initial public offering early this year, saw its share price close up almost 300% at $13.35 on 31 December on news that its sole drug candidate, Pyridorin, was found to be safe in a cardiac safety study.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel